Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution studyAstrid J. Schraa, Grietje Molema, Lou F. M. H. de Leij et al.|International Journal of Cancer|2002Cited by 73
Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal FibrosisJai Prakash, Robbert J. Kok, Maria Sandovici et al.|Journal of Pharmacology and Experimental Therapeutics|2006Cited by 57
RENAL-SELECTIVE DELIVERY AND ANGIOTENSIN-CONVERTING ENZYME INHIBITION BY SUBCUTANEOUSLY ADMINISTERED CAPTOPRIL-LYSOZYMEJai Prakash, Robbert J. Kok, Klaas Poelstra et al.|Drug Metabolism and Disposition|2005Cited by 24